SAN FRANCISCO --(BUSINESS WIRE)--Oct. 14, 2020-- Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the closing of its initial public offering of

SAN FRANCISCO--( BUSINESS WIRE )-- Spruce Biosciences, Inc ., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the pricing of its initial public offering of 6,000,000 shares of

- Dr. Rosh Dias appointed Chief Medical Officer - - Dan Spiegelman appointed to Board of Directors - SAN FRANCISCO--( BUSINESS WIRE )-- Spruce Biosciences , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant

New website and patient resource will enable adults with Congenital Adrenal Hyperplasia (CAH) to register interest in Spruce’s CAHmelia clinical program, launching later this year San Francisco, Calif.  – May 12, 2020 – Spruce Biosciences, a late-stage clinical development company focused on

San Francisco, Calif.  – May 6, 2020 – Spruce Biosciences, a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, today announced the appointments of Samir Gharib, MBA, CPA, as Chief Financial Officer (CFO), and Dasharatha

– Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications – Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap, Rock Springs Capital, Aisling Capital, Surveyor Capital (a Citadel company) and